about
Disease risk score as a confounder summary method: systematic review and recommendationsVarenicline and Risk of Self-Harm: A Nested Case-Control StudyThimerosal-containing vaccines and autism: a review of recent epidemiologic studies.Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials.Initial uptake of the Ontario Pharmacy Smoking Cessation Program: Descriptive analysis over 2 years.Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study.Appropriate prescribing in nursing homes demonstration project (APDP) study protocol: pragmatic, cluster-randomized trial and mixed methods process evaluation of an Ontario policy-maker initiative to improve appropriate prescribing of antipsychoticsPersistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study.First renin inhibitor, aliskiren, for the treatment of hypertension.Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillationComparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort studyPegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.Diffusion of Innovations model helps interpret the comparative uptake of two methodological innovations: co-authorship network analysis and recommendations for the integration of novel methods in practice.The appropriateness and persistence of testosterone replacement therapy in Ontario.Performance of the disease risk score in a cohort study with policy-induced selection bias.Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access.Proceed with caution: The possible impact of preferred-provider networks.Development of phytosanitary cold treatments for oranges infested with Bactrocera invadens and Bactrocera zonata (Diptera: Tephritidae) by comparison with existing cold treatment schedules for Ceratitis capitata (Diptera: Tephritidae).Variation in the days supply field for osteoporosis medications in Ontario.Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities.Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma.Impact of Unrestricted Access to Pregabalin on the Use of Opioids and Other CNS-Active Medications: A Cross-Sectional Time Series Analysis.Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes: A Population-Based Study.Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study.Self-Monitoring of Blood Glucose Levels: Evaluating the Impact of a Policy of Quantity Limits on Test-Strip Use and Costs.Off-label use of inhaled tobramycin in Ontario, Canada.Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis—reply to Pazianas and AbrahamsenEffects of dextromethorphan on in vitro contractile responses of mouse and rat urinary bladders"Like being put on an ice floe and shoved away": A qualitative study of the impacts of opioid-related policy changes on people who take opioidsComprehensive Drug-Class Review Framework for improved evidence-based drug policy and formulary modernizationTopical corticosteroids and type 2 diabetes mellitus: a critical appraisal
P50
Q26999267-2DC3241A-CF21-4A3D-B676-3F6BC9A606B1Q28554332-13DA3696-6CD7-4BF1-8A29-2FE8F25190E3Q34477265-BCB26E6D-3773-4367-8886-DB79C433E511Q34621157-9CC2FE40-9CEE-4EB1-BB3A-D5E24EC33424Q34961922-9E20C2A6-4787-4E05-A9F3-8808AFED522DQ35241128-9AA82A9A-CE3B-4272-882D-01D385C53E12Q36742413-4676A740-90B3-4286-BFC3-7E880354129CQ37022906-80FB554A-FED3-42BB-88F1-AE69E261C7FDQ37273380-EF05BBED-A0C2-4B38-B8C0-F867A7FAF664Q37578065-AB68D558-E7AD-4FB9-BD44-5A6321ECFDC5Q37701830-8F397954-0078-4E17-9876-CD9AB173915FQ38068457-D2637EC3-A528-4CFB-BA9A-698C738F91D2Q38167249-0A35E6DD-601C-4356-86B3-48D6F4C5AAFEQ38653536-54582895-69D7-427A-89A6-8E4E1E766158Q38676353-B1AE1151-82A8-48D0-8FEE-1DA0FE80F944Q38702184-F0EF8746-5617-4ED7-B8C0-7D32549C8843Q39065435-D8E35C49-31ED-4BA8-9583-6D5BE08B8FD2Q39486784-2EF52AC9-CC50-49A8-AD19-B6A442A65467Q40361680-93592F98-3960-4652-B1D8-981393684DEBQ41555935-765A22C0-9EE4-4313-A177-E7D397087318Q41788907-AEEBEACC-6490-4D1C-82C6-903E947A8FE6Q44306049-CE9C94E1-AFFA-496D-9E46-B9B458D6E08CQ45364591-1F6E3C76-0A5B-4AB5-A56D-0DE4A28109FCQ47640531-809FE3BA-6775-48C4-BF99-17DA55D60951Q47911450-552E4447-43CD-4845-A0C3-FB7675D41900Q50775835-A9F6678C-DAF6-41D4-A77A-A1015902AA26Q51074570-47B056E7-8609-46FD-A8E7-0DD6E3DD1B89Q51303699-6A343AC0-2E7A-4C31-ADD6-873E12AEAE93Q53094580-EF3C9455-E083-403A-A85C-F296F93F635FQ54225890-24CE9901-7157-474A-9A13-0B208A82F276Q55415316-23E009B6-DA89-45E8-B5C3-6F2EAAB05DDEQ57695476-E793A7DC-0048-4ECC-8C7B-14EF85215C23Q60498154-AC9E52B2-E57C-441B-8D2A-8ADA808EA821Q91238160-F2CF5D1C-A88B-400F-A775-E520F41C6687Q91651991-930ED89B-6063-4881-9323-285BA1D80671Q92293202-9F92D7F3-9370-4891-B522-F285658ADBDE
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mina Tadrous
@ast
Mina Tadrous
@en
Mina Tadrous
@es
Mina Tadrous
@nl
Mina Tadrous
@sl
type
label
Mina Tadrous
@ast
Mina Tadrous
@en
Mina Tadrous
@es
Mina Tadrous
@nl
Mina Tadrous
@sl
prefLabel
Mina Tadrous
@ast
Mina Tadrous
@en
Mina Tadrous
@es
Mina Tadrous
@nl
Mina Tadrous
@sl
P106
P1153
15053875600
P21
P31
P496
0000-0003-1911-6129
P569
2000-01-01T00:00:00Z